45 results
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
17 Sep 19
Current report (foreign)
8:06am
Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD) is Phase3-ready following a successful Type B End of Phase 2 meeting with the FDA and agreed … for the treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”), leflutrozole for the treatment of hypogonadotropic hypogonadism (“HH
425
MREO
Mereo Biopharma Group Plc
11 Dec 18
Business combination disclosure
1:16pm
OSTEOGENESIS IMPERFECTA (OI) 16 An orphan genetic chronic bone disorder characterised by fragile bones that break easily ̴ 6.2 OI cases per 100,000 population … in alpha - 1 antitrypsin deficiency: An analysis of the RAPID/RAPID Extension trials. Chronic Obstr Pulm Dis. 2017; 4(1): 34 - 44. Mereo BioPharma Group
425
MREO
Mereo Biopharma Group Plc
12 Feb 19
Business combination disclosure
12:00am
DISEASE 19 Mereo BioPharma Group plc
Mereo BioPharma Group plc OSTEOGENESIS IMPERFECTA (OI) 20 An orphan genetic chronic bone disorder characterised … on bioma rkers of elastin degradation in alpha - 1 antitrypsin deficiency: An analysis of the RAPID/RAPID Extension trials. Chronic Obstr Pulm Dis
425
OncoMed Pharmaceuticals Inc
7 Jan 19
Business combination disclosure
11:50am
Group plc OSTEOGENESIS IMPERFECTA (OI) 16 An orphan genetic chronic bone disorder characterised by fragile bones that break easily ̴ 6.2 OI cases per … of elastin degradation in alpha - 1 antitrypsin deficiency: An analysis of the RAPID/RAPID Extension trials. Chronic Obstr Pulm Dis. 2017; 4(1): 34 - 44
425
MREO
Mereo Biopharma Group Plc
15 Feb 19
Business combination disclosure
6:50am
IMPERFECTA A SEVERE GENETIC BONE DISEASE 19 Mereo BioPharma Group plc
Mereo BioPharma Group plc OSTEOGENESIS IMPERFECTA (OI) 20 An orphan genetic chronic … . Chronic Obstr Pulm Dis. 2017; 4(1): 34 - 44. Mereo BioPharma Group plc
BCT - 197 ACUMAPIMOD (ACQUIRED FROM NOVARTIS IN 2015)
Mereo BioPharma Group plc
6-K
EX-99.1
u64yq03dwj86eki
9 Jun 20
Publication of Circular and Notice of General Meeting
4:15pm
425
i0zw1
12 Mar 19
Business combination disclosure
9:27am
6-K
EX-99.1
rp7d342txfadtrt
22 May 20
Annual General Meeting
9:31am
6-K
EX-99.1
ykl8j41
7 Oct 19
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
12:23pm
6-K
EX-99.1
g467h
12 Feb 20
Mereo Biopharma Announces Update on Distribution Related to Contingent Value Rights Following Recent Oncologie Licensing Agreement for Navicixizumab
9:48am
6-K
EX-99.1
7kl5enwfq zjje
26 Oct 21
Mereo BioPharma Receives U.S. Orphan Drug Designation for alvelestat in About Mereo BioPharma
10:07am
6-K
EX-99.1
gh3cr03k
27 May 20
Notice of Annual General Meeting
7:37am
6-K
EX-99.1
1im4 bctvscfe
2 Jun 21
Current report (foreign)
8:24am
6-K
EX-99.1
4b1er
27 Mar 20
Business Update and Directorate Change
9:09am
6-K
EX-99.1
6i23m7n
17 Oct 22
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of
7:16am
6-K
EX-99.1
lqwg5f9ogz d6k
19 Feb 20
Mereo BioPharma Announces Equity Investment of $3 Million from New U.S. Institutional Investor
9:32am
6-K
EX-99.1
kg7zs8uxxj9 yh93
28 Feb 20
Current report (foreign)
9:46am
6-K
EX-99.1
vw1p4xyljky3vv
29 Sep 20
Current report (foreign)
7:08am
6-K
EX-99.1
xqcopp
10 Feb 20
Current report (foreign)
7:20am
6-K
EX-99.1
me1kzss5gfkg1lx
13 Jan 20
Mereo BioPharma and Oncologie Enter into Global Licensing Agreement for Navicixizumab
8:26am